Reports Q3 revenue $4.61M, consensus $2.91M. “Voyager continues to advance our prioritized programs towards the clinic: the initiation of GLP toxicology studies for our anti-tau antibody VY-TAU01 keeps us on track for an anticipated IND filing in the first half of 2024. Further, we expect to select a development candidate for our wholly-owned SOD1 ALS gene therapy program by end-of-year, and our broader gene therapy pipeline presents multiple opportunities for INDs in 2025 across our wholly-owned and partnered programs,” said Alfred W. Sandrock, Chief Executive Officer of Voyager. “In addition to advancing our pipeline, we continue to evolve and refine our neurotropic TRACER AAV capsids and look forward to continuing to share data at scientific meetings.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
- Is VYGR a Buy, Before Earnings?
- Voyager Therapeutics management to meet with Oppenheimer
- Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
- Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference